PHÂN TÍCH CHI PHÍ SỬ DỤNG THUỐC TẠI BỆNH VIỆN LÊ VĂN THỊNH GIAI ĐOẠN 2018-2023

Abstract

Objective: This study aimed to evaluate the costs associated with drug utilization at Lê Văn Thịnh Hospital (LVTH) over the six-year period from 2018 to 2023. Materials and Methods: A cross-sectional descriptive study was conducted using retrospective analysis of drug utilization data for patients covered by health insurance. Drug costs were categorized and analyzed based on therapeutic scope, origin of drugs, active ingredients, route of administration, technical classifications, and pharmacological classifications. The cost data were further examined across three distinct time intervals (2018-2019, 2020-2021, 2022-2023) and cumulatively for the entire study period. Results: A total of 653 active ingredients reimbursed under the health insurance scheme were utilized at LVTH during the study period. Outpatient drug expenditures accounted for 82.7% of the total costs. Cardiovascular drugs represented the largest proportion of expenditures, comprising one-third of the total drug costs, with more than 50% allocated to antihypertensive medications. Drugs for parasitic diseases and endocrine disorders ranked second and third, respectively, in terms of expenditure for insured patients. No significant shifts were observed in the cost distribution of drug categories across the three analyzed time intervals. Among the top 10 most expensive active ingredients, six were single-component drugs, while four were combination formulations, primarily belonging to the cardiovascular, endocrine, and parasitic drug categories. Conclusion: This study highlights key characteristics of drug cost structures under the health insurance scheme at LVTH from 2018 to 2023. The findings provide valuable insights to inform financial planning and resource allocation, enabling strategic adjustments to improve the efficiency of drug utilization, optimize treatment outcomes, and ensure sustainable hospital budgeting.